ServiziMenu principaleHome
You are here:  > Educational Opportunities > Past events > 2008 > Leukaemias: Molecular Insights to Treatment Paradigms
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

Leukaemias: Molecular Insights to Treatment Paradigms

Not eligible for ESCO credits

07.03.2008  -  09.03.2008

Mumbai, India




The programme will focus on adult and childhood leukaemias, an area in which significant advances have been made in many aspects including molecular insights, better diagnostics, risk stratifications, classification and treatment in particular molecularly targeted therapies.
Recent advances in acute and chronic leukaemias, myelodysplastic syndromes, myeloproliferative disorders, supportive and adjunctive therapies will be discussed through didactic lectures, debates, case-based and slide presentations with interactive questions and answers sessions. The meeting will furthermore provide a platform for selected poster presentations.

The conference is held in partnership with

INCTR  (International Network for Cancer Treatment and Research)


in collaboration with:

European School of Haematology

Indian Society of Medical and Pediatric Oncology

Indian Co-operative Oncology Network

Mumbai Haematology Group

and under the auspices of

UICC (International Union Against Cancer)


General information

Conference venue
ITC Hotel - The Grand Central
Dr. Babasaheb Ambedkar Road, Parel, Mumbai


Organising secretariat (programme, registration, invitation letters, abstract submission)
Chatrina Melcher, European School of Oncology, Bellinzona Office
Ospedale Regionale - CH-6500 Bellinzona, Switzerland
Tel: +41 91 811 8050, Fax: +41 91 811 8051, e-mail: eso2@esoncology.org

Local organiser (onsite logistics, local registration, hotel accommodation, tours)
Vama Events
34, 1st Floor,Keshav Bhuvan, Lady Jamshedji Road - Mahim, Mumbai 400 016, India
Tel: +91 22 2438 3498, Fax:  +91 22 2438 3499, e-mail: vamahospitality@hotmail.com

Letter of invitation
If you require an official letter of invitation in order to attend the conference, please write to the organising secretariat at eso2@esoncology.org.
The letter will assist delegates who need to obtain their governments or departments permission to attend the conference or obtain required visa from Indian-Mission abroad.
The letter of invitation will be released to fully registered participants and does not entitle registrant from exemption in fee.

Certificate of attendance and CME accreditation
All participants will be issued a certificate of attendance at the close of the conference.
The conference has achieved CME accreditation approval by the Accreditation Council for Oncology in Europe, supporting that the programme has been recognised a high quality value both from a scientific and didactic point of view. The request for European endorsement of ACOE accreditation was submitted to the European Union of Medical Specialists (UEMS) clearing house, the EACCME. The conference has been granted European endorsement by the UEMS and awarded 15 European Continuing Medical Education Credits (ECMEC). The ECMEC will be recognised within the different European States which have agreed to participate in this European system, and by the American Medical Association (AMA) as AMA PRA Category 1 Credits.

Official language
The official language is English, no translation will be provided.

The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration.

The organisers bear no responsibility for untoward events in connection with, before, during and after the conference. Participants are strongly advised to take out their own personal and travel insurance coverage.


Authors of submitted abstracts will be notified on the outcome by 15 February. The author of abstracts accepted for presentation will be required to register to the conference.

The five best abstracts will be accepted for oral presentation and the Best Poster Award.